Interleukin 21 inhibits cancer-mediated FOXP3 induction in naïve human CD4 T cells

Cancer Immunology, Immunotherapy

Volumn 66, Issue 5, 2017, Pages 637-645

  Kannappan, Vinodh ^a   Butcher, Kate ^a   Trela, Malgorzata ^a   Nicholl, Iain ^a   Wang, Weiguang ^a   Attridge, Kesley ^a,b  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

Author keywords

Anti tumour immunity; FOXP3; IL 21; Immunosuppression; Immunotherapy; Regulatory T cells

Indexed keywords

CD45RA ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ARTICLE; CANCER IMMUNOLOGY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; A-549 CELL LINE; CELL PROLIFERATION; HCT 116 CELL LINE; IMMUNOLOGY; NEOPLASM;

A549 CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; HCT116 CELLS; HUMANS; INTERLEUKINS; NEOPLASMS;

EID: 85013898901     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-1970-6     Document Type: Article

References (37)

1. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759–767. doi:10.1002/ijc.25429
2. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN (2008) Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 14:5166–5172. doi:10.1158/1078-0432.CCR-08-0320
3. El Andaloussi A, Lesniak MS (2007) CD4 + CD25 + FoxP3 + T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 83:145–152. doi:10.1007/s11060-006-9314-y
4. Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, Sampson JH, Mitchell DA (2015) Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 64:419–427. doi:10.1007/s00262-014-1651-7
5. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen Y-T, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538–18543. doi:10.1073/pnas.0509182102
6. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128–3133
7. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823–832
8. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE, Bigner DD, Dranoff G, Sampson JH (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294–3302. doi:10.1158/0008-5472.CAN-05-3773
9. El Andaloussi A, Han Y, Lesniak MS (2006) Prolongation of survival following depletion of CD4+ CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 105:430–437. doi:10.3171/jns.2006.105.3.430
10. Li Y, Yee C (2008) IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111(1):229–235
11. Zhou G, Drake CG, Levitsky HI (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107:628–636. doi:10.1182/blood-2005-07-2737
12. Clough L, Wang C, Schmidt E, Booth G, Hou T, Ryan G, Walker L (2008) Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J Immunol 180:5393–5401
13. Van Belle TL, Nierkens S, Arens R, Herrath von MG (2012) Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity 36(6):1060–1072. doi:10.1016/j.immuni.2012.04.005
14. Peluso I, Fantini M, Fina D, Caruso R, Boirivant M, MacDonald T, Pallone F, Monteleone G (2007) IL-21 counteracts the regulatory T cell-mediated suppression of human CD4 + T lymphocytes. J Immunol 178:732–739
15. Attridge K, Wang CJ, Wardzinski L, Kenefeck R, Chamberlain JL, Manzotti C, Kopf M, Walker LSK (2012) IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 119(20):4656–4664. doi:10.1182/blood-2011-10-388546
16. Attridge K, Kenefeck R, Wardzinski L, Qureshi OS, Wang CJ, Manzotti C, Okkenhaug K, Walker LSK (2014) IL-21 Promotes CD4 T Cell Responses by Phosphatidylinositol 3-Kinase-Dependent Upregulation of CD86 on B Cells. J Immunol 192:2195–2201. doi:10.4049/jimmunol.1302082
17. Fröhlich A, Kisielow J, Schmitz I, Freigang S, Shamshiev AT, Weber J, Marsland BJ, Oxenius A, Kopf M (2009) IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324:1576–1580. doi:10.1126/science.1172815
18. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom T, Oukka M, Kuchroo V (2007) IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature 448:484–487
19. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448:480–483. doi:10.1038/nature05969
20. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, Levy DE, Leonard WJ, Littman DR (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8:967–974. doi:10.1038/ni1488
21. Chen W, Jin W, Hardegen N, Lei K-J, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4+ CD25- naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886. doi:10.1084/jem.20030152
22. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238. doi:10.1038/nature04753
23. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C (2007) Tumor evasion of the immune system by converting CD4+ CD25- T cells into CD4+ CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178:2883–2892
24. Crane CA, Ahn BJ, Han SJ, Parsa AT (2012) Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro-oncol 14:584–595. doi:10.1093/neuonc/nos014
25. Alvero AB, Montagna MK, Craveiro V, Liu L, Mor G (2012) Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Am J Reprod Immunol 67:256–265. doi:10.1111/j.1600-0897.2011.01068.x
26. Morgan ME, van Bilsen JHM, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, Elferink BG, van der Zanden L, de Vries RRP, Huizinga TWJ, Ottenhoff THM, Toes REM (2005) Expression of FOXP3 mRNA is not confined to CD4+ CD25+ T regulatory cells in humans. Hum immunol 66:13–20. doi:10.1016/j.humimm.2004.05.016
27. Wang J, Ioan-Facsinay A, van der Voort EIH, Huizinga TWJ, Toes REM (2007) Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 37:129–138. doi:10.1002/eji.200636435
28. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK (2007) Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345–354. doi:10.1093/intimm/dxm014
29. Shen Y, Wei Y, Wang Z, Jing Y, He H, Yuan J, Li R, Zhao Q, Wei L, Yang T, Lu J (2015) TGF-β regulates hepatocellular carcinoma progression by inducing Treg cell polarization. Cell Physiol Biochem 35:1623–1632. doi:10.1159/000373976
30. Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, Goedegebuure PS, Linehan DC (2009) Tumor-derived TGF-beta mediates conversion of CD4+ Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother 32:12–21. doi:10.1097/CJI.0b013e318189f13c
31. Yang Z-Z, Grote DM, Ziesmer SC, Xiu B, Yates NR, Secreto FJ, Hodge LS, Witzig TE, Novak AJ, Ansell SM (2013) Soluble and membrane-bound TGF-β-mediated regulation of intratumoral T cell differentiation and function in B-cell non-Hodgkin lymphoma. PLoS One 8:e59456. doi:10.1371/journal.pone.0059456
32. D’Cruz LM, Klein L (2005) Development and function of agonist-induced CD25+ Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 6:1152–1159. doi:10.1038/ni1264
33. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6:1142–1151. doi:10.1038/ni1263
34. La Rosa de M, Rutz S, Dorninger H, Scheffold A (2004) Interleukin-2 is essential for CD4 + CD25 + regulatory T cell function. Eur J Immunol 34:2480–2488. doi:10.1002/eji.200425274
35. Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107:2409–2414. doi:10.1182/blood-2005-06-2399
36. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, Long LM, Bernstein D, Hill BJ, Douek DC, Berzofsky JA, Carter CS, Read EJ, Helman LJ, Mackall CL (2005) Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+ CD25+ regulatory T cells. Nat Med 11:1238–1243. doi:10.1038/nm1312
37. Spolski R, Leonard WJ (2014) Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov 13:379–395. doi:10.1038/nrd4296